In the JMIL-only population , no significant OS difference observed between treatment arms ( adjusted HR = 1.03 [ 95 % CI : 0.77-1 .39 , p = 0.822 ] ; unadjusted HR = 0.996 [ 95 % CI : 0.74-1 .33 , p = 0.980 ] ) , nor for other secondary efficacy endpoints .